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An increase in phosphorylated tau (p-tau) is associatedwith Alzheimer’s disease (AD), and brain hypoxia.
Investigation of the association of residue-speciﬁc tau hyperphosphorylation and changes in cognition,
leads to greater understanding of its potential role in the pathology of memory impairment. The aims
of this study are to investigate the involvement of the main metabolic kinases, Liver Kinase B1 (LKB1)
and Adenosine Monophosphate Kinase Protein Kinase (AMPK), in tau phosphorylation-derived memory
impairment, and to study the potential contribution of the other tau kinases and phosphatases including
Glycogen Synthase Kinase (GSK-3), Protein kinase A (PKA) and Protein Phosphatase 2A (PP2A). Spatial
memory and learning were tested in a rat global brain ischemic model of reversible cardiac arrest (CA).
The phosphorylation levels of LKB1, AMPK, GSK-3, PP2A, PKA and tau-speciﬁc phosphorylation were
assessed in rats, subjected to ischaemia/reperfusion and in clinically diagnosed AD and normal human
brains. LKB1 and AMPK phosphorylation increased 4 weeks after CA as did AMPK related p-tau (Ser262).
The animals showed unchanged levels of GSK-3 speciﬁc p-tau (Ser202/Thr205), phospho-PP2A (Tyr307),
total GSK-3, PP2A, phospho-cAMP response element-binding protein (CREB) which is an indicator of
PKA activity, and nomemory deﬁcits. AD brains had hyperphosphorylated tau in all the residues of Ser262,
202 205 172 9Ser and Thr , with increased phosphorylation of both AMPK (Thr ) and GSK-3 (Ser ), and reduced
PP2A levels. Our data suggests a crucial role for a combined activation of tau kinases and phosphatases
in adversely affecting memory and that hyperphosphorylation of tau in more than one speciﬁc site may
be required to create memory deﬁcits.
© 2016 The Authors. Published by Elsevier Ltd on behalf of International Brain Research Organization.
This is an open access article under the CC BY-NC-ND license. Introduction
Many studies have reported cognitive behaviour and mem-
ry impairments as the long-term outcomes of brain hypoxia
Pohjasvaaraet al., 1998;Madureiraet al., 2001;Mateenet al., 2011;
un et al., 2014). The relationship of Alzheimer’s disease (AD) type
ementia and a history of head injury has been noted (Plassman
t al., 2000) and a suggested explanation links hypoxia and over-
xpression of phosphorylated tau (p-tau), seen in head injury and
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AD demonstrated in an animal model of cerebral hypoxia (Castro-
Alvarez et al., 2011; Iliff et al., 2014; Zhang et al., 2014; Asai et al.,
2015).
Tau hyperphosphorylation is one of the suggested theories
explaining AD pathophysiology (Stoothoff and Johnson, 2005;
Hanger et al., 2009). Previous reports demonstrated that hypoxic
insults to cortical neurons triggered pathological cascades such as
tau hyperphosphorylation (Chen et al., 2003). Other evidence from
animal studies indicated that hypoxia and ischaemia facilitated the
generation of AD pathological hallmarks in rats via many mech-
anisms, resulting in hyperphosphorylated tau and beta amyloid
(Stephensonet al., 1992;Xie et al., 2005; Castro-Alvarez et al., 2011;
Zhang et al., 2014).
A balance of activity between glycogen synthase kinase-3
(GSK-3) and protein phosphatase 2A (PP2A), as the main tau
kinase and phosphatase has been reported as the core contributor
































































and Besheer, 2006) as follows: (Time around novel – Time aroundS. Majd et al. / IBR
n deﬁning tau phosphorylation/dephosphorylation status (Eldar-
inkelman, 2002; Liu et al., 2005). This theory is supported by
everal reports from post-mortem studies of brains from clini-
ally diagnosed AD patients which demonstrated tangle-bearing
eurons associated with a high level of GSK-3 (Lovell et al.,
004; Hernandez et al., 2013) and a reduction of activity of PP2A
hrough increasing its phosphorylation at Tyr307. Phosphoryla-
ion of PP2A at Tyr307 has also been reported in tangle-bearing
eurons in patients with AD (Gong et al., 1995; Sontag et al.,
004). These ﬁndings suggest that GSK-3 and PP2A may be
nvolved in the promotion of tau aggregation in AD (Hanger et al.,
007; Hanger and Noble, 2011), however more recent reports
ave shown that some hyperphosphorylated residues of tau in AD
rains, are insensitive to the action of GSK-3 and PP2A (Guerra-
raiza et al., 2007; Hanger et al., 2007; Hanger and Noble, 2011),
aising the question of the importance of the other kinases as
ell as the site-related phosphorylation of tau in generating AD
athology.
It appears that tau phosphorylation is dependent on more than
ust GSK-3 and PP2A. Tau can be phosphorylated at over 40 sites
f Ser/Thr residues (Hanger et al., 2007), by a series of other kinases
ncludingProteinkinaseA (PKA) (Liu et al., 2006), Cyclin-dependent
inase 5 (cdk5) and the Adenosine Monophosphate Kinase Pro-
einKinase (AMPK) family (Johnson andStoothoff, 2004; Chatterjee
t al., 2009; Castro-Alvarez et al., 2011; Thornton et al., 2011;
oshida and Goedert, 2012), all these kinases could be activated
y neuronal stress.
A link exists between tau phosphorylation and neuronal stabil-
ty in response to stressful conditions such as ischaemia (Dewar
nd Dawson, 1995; van der Harg et al., 2014). An early response
o ischaemia/hypoxia is activation of the master regulator of
ellular metabolism, Liver Kinase B1 (LKB1) and subsequently
MPK-related kinases, which also possess tau kinase activity.
MPK kinases mainly phosphorylate tau at Ser262, a GSK-3-
nsensitive site that is phosphorylated early in the process of
D (Augustinack et al., 2002; Guerra-Araiza et al., 2007; Mairet-
oello et al., 2013; Domise et al., 2016). Phosphorylation of tau at
er262 is reported as a critical component of tau-induced toxicity
Iijima et al., 2010). The correlation between the AMPK mod-
latory function on metabolism in response to hypoxia/anoxia
Hardie, 2011) and its tau kinase activity suggests a metabolic
ased hypothesis for the pathophysiology of AD. However to what
xtend the phosphorylation of Ser262, an AMPK kinases-sensitive
ite of tau without the involvement of the other major kinases
nd phosphatases of tau could affect thememory function requires
nvestigation.
We previously demonstrated in a reversible rat model of car-
iac arrest (Majd et al., 2016), that brain ischaemia signiﬁcantly
ttenuated p-tau within the ﬁrst few minutes. In this study, we
nvestigated AMPK-sensitive tau phosphorylation of Ser262 due
o changes in LKB1/AMPK activity in response to alterations in
rain oxygenation. We showed that recovery from global brain
schaemia is associated with hyperactivity of AMPK and tau hyper-
hosphorylation at Ser262. Because in our model the observed
yperphosphorylation at Ser262 alone was not associated with
bserved changes in memory and learning, we suggest that this
esidue-speciﬁc hyperphosphorylation in the absence of changes
n the levels of other tau kinases and phosphatases such as PKA,
SK-3 and PP2A, was not enough to create an impact on memory
nd learning in rats. Combining the results of our animal experi-
ents, with the ﬁndings from our human studies of Alzheimer’s
atients, we suggest the involvement of at least three enzymes;
MPK,GSK-3andPP2A ingenerating theneuropathological forms




The animal studywas approvedby theAnimal Ethics Committee
of Flinders University and was completed in accordance with the
South Australian Prevention of Cruelty to Animals Act 1985 follow-
ing the Australian Code of Practice for the Care and Use of Animals
for Scientiﬁc Purposes, 2004.
2.2. Animal preparation
Adult Sprague-Dawley rats (2 months, 250–350 g, female) from
Laboratory Animal Services (Adelaide University) were used, in 4
experimental groups (n = 6 in each). The experimental time line
is illustrated in Fig. 1. Reversible cardiac arrest (CA) was gener-
ated under general anaesthesia, using our previously described
model (Majd SP et al., 2016). In this model electrocardiogram
leads are attached to the chest, allowed constant recording of car-
diac electrical activity and deﬁbrillation via a deﬁbrillator/monitor
(Philips HeartStart MRX, Philips Healthcare INC, USA). Oxygen sat-
uration (SpO2) and pulse rate were continuously monitored via a
Pulse-oximeter. Ventilation with supplemental oxygen was per-
formed via endotracheal intubation using a volume-controlled
small animal ventilator (New England Medical Instruments
Inc, Medway, Massachusetts, USA). The body temperature was
checked by rectal probe, and was maintained with a heating
lamp.
CA was achieved using two phases of transoesophageal alter-
nating current (50Hz 24V followed by 50Hz 18V) via a pacing
catheter with two end ring electrodes and a 0.5 cm gap inserted
in the oesophagus to a depth of 6–6.5 cm. Ventilation was
stopped during CA. A post CA rhythm of ventricular ﬁbrillation
was deﬁbrillated using 8 J. Effective circulation was conﬁrmed
by a pulse oximeter reading, a SpO2 of 85–95% or greater was
maintained. Two min of CA was followed by post resuscita-
tion perfusion (60 min: short-term recovery; 4 weeks: long-term
recovery).
To obtain brain samples, the brains were perfused with cold
Phosphate Buffered Saline, half of the specimen was frozen in liq-
uid nitrogen after isolation and kept in a −80 ◦C freezer and half
was ﬁxed in 10% paraformaldehyde. Five m sections of the brain
containing the hippocampus and cortex were placed on Poly-d-
Lysine coated slides, deparafﬁnized in xylene, and dehydrated in
ethanol.
2.3. Novel object recognition (NOR)
Toassess learningandmemory, the animal’s response to a famil-
iar object compared to its response to a novel object was tested
(n = 6 in this group), before CA and after 4 weeks recovery. The ani-
mals were given a 30 min habituation period prior to starting the
test, to gain familiarity with the arena. In the acquisition stage of
the test the rats were allowed to explore two identical objects in
an experimental chamber for 10 min, the exploration time around
each object was measured. Memory retention was assessed when
one of the identical objects was replaced with a novel one dur-
ing a retention trial (10 min) either after an inter-trial interval of
1 h of (representing the short-term memory retention) or after
24 h (representing long-term memory retention). The time spent
exploring the objects was analysed as previously described (Bevinsfamiliar object)/(Time around novel object + Time around familiar
object) and was analysed using ANY-maze software (Stoeling Co,
Wood Dale, IL, USA).













































rabbit-polyclonal antibodies (#2532) were purchased from Cell
Signalling Australia. Mouse NeuN antibody (MAB377) was pur-
chased from Merck Millipore Australia. Secondary antibodies of
HRP donkey anti-mouse (715-036-150), anti-rabbit (711-035-
Table 1
List of the human cases used for protein assessment via western blot analysis.
Case number Sex Age (yr) Diagnosis Region PMI (hrs)
SA0163 F 72 AD Hippocampus 12
SA0168 F 82 AD Hippocampus 8
SA0215 F 77 AD Hippocampus 17
SA0237 M 81 AD MFG 21
SA0244 M 63 AD Hippocampus 23
SA0248 M 83 AD Hippocampus 37
SA0112 (C) F 86 MLI MFG 6
SA0214 (C) M 64 HP Hippocampus 36ig. 1. Timeline of the animal study: behavioural test ofMorrisWaterMaze (MWM)a
efore and 4 weeks after cardiac arrest (CA). Western blot and immuno-staining we
.4. Morris Water Maze (MWM)
Spatial memory was assessed using a Morris Water Maze
MWM) as described previously (Tonkiss et al., 2003). Each rat was
ubjected to two complete series of MWM assessments, before CA
nd after CA (n = 6 in this group) Individual variations in learn-
ng and memory ability between animals were accounted for by
sing each rat as its own control and comparing memory after
A with memory before CA in the same animal. A circular pool
150 cm in diameter with 60 cm high walls) was divided into 4
qual quadrants, ﬁlled with water (to a depth of 40 cm) that was
ade opaquewith skimmilk (99% fat free). Thewater temperature
as adjusted to 25◦ (±0.5) C. Coloured shapes were placed on the
all of the room, as visual cues. The rat’s movement was recorded
sing a camera above the pool and a computer running the ANY-
aze software (Stoeling Co,WoodDale, IL, USA). Before starting the
rial phase of the test, each rat was allowed an adaptation period of
0min to the roomenvironment. Each test contained three phases:
isible-platform training, probe test and hidden-platform training.
.4.1. Training phase with visible-platform
The visible platform (10 cm in diameter), was placed in one
uadrant of the pool (North West: NW, Fig. 5), 1.5 cm above the
ater and easily visible to the rat. Each rat was given 1 min on the
latform before undergoing 3 swim training trials.
Each rat was trained to remember the location of the visible
latform, by being released from three different quadrants (North-
ast: NE, South-east: SE and South-west: SW) facing the wall at a
istance of 30–45 cm. The rats were given 1 min each in each trial
o reach to the platform. If the rat was not able to ﬁnd the platform
ithin 1 min, it was guided by the examiner’s hand toward the
latform and the time was recorded as 1 min. Upon standing on
he platform, the animal was allowed to remain there for 15 s. Each
at was subjected to 12 trials over two days (6 trials each day) in
otal, with a 45 min interval time between each trial, when the rat
as dried and placed in a heated cage.
For each rat, the platform location remained unchanged while
he starting position was changed randomly on each trial, making
ure that each starting location was repeated twice in each day
ontaining 6 trials.
.4.2. Probe test
The probe test was performed on the day three of the test. Dur-
ng each test the platform was removed and the rat was released
rom four starting points of NW,NE, SWand SE. To assess the estab-
ishment of the learning strategy (spendingmore time in the target
uadrant) the rats were given 1 min to swim freely during each of
he four trials, and the time spent in each quadrant was calculated..4.3. Training phase with hidden-platform
In the hidden phase of the test, the platform was submerged
1 cm under water). Two sets of 6 trials (12 trials in total) werevelObject Recognition (NOR) formemory and learning assessmentwereperformed
ed for protein assessment and protein visualization.
performed with a 30–45 s recovery period between each trial and
30–45 min between the ﬁrst set (6 trials) and the second set of 6
trials. Each rat was given 1 min to ﬁnd the platform, followed by
a 15 s reinforcement time when the rat remained on the platform.
If the rat was not able to reach the platform within 1 min, it was
guided by the examiner’s hand toward the platform and the time
were recorded as 1 min. Time to reach the platform (latency) and
time spent in the target quadrant was recorded and analysed using
a video tracking system (Stoeling Co, Wood Dale, IL, USA).
2.5. Human experiments
Brain tissues from six clinically diagnosedAD (conﬁrmedpatho-
logically postmortem) and three control cases (without conﬁrmed
diagnosed neurological pathology postmortem) were obtained
from the National Health andMedical Research Council South Aus-
tralian Brain Bank and analysed using a western bolt and antibody
technique. Table 1 provides a list of the brain regions examined and
the case details.
2.6. Antibodies
Phosphorylated LKB1 mouse-monoclonal (Ser431; sc-271924),
LKB1 rabbit-polyclonal (H-75; sc-28788), p-tau rabbit-polyclonal
(Ser262; sc-101813), p-GSK-3 goat-polyclonal (Ser9; sc-11757),
p-PP2A-C/ mouse-monoclonal (F-8; sc-271903), tau mouse-
monoclonal (A-10; sc-390476), GSK-3 rabbit-polyclonal (H-76;
sc-9166), p-CREB (Ser133; sc-101663) rabbit-polyclonal and PP2A-
A goat-polyclonal antibodies (C-20; sc-6112) were purchased
from Santa Cruz. Mouse-monoclonal GFAP and Ser202/Thr205 (AT8)
antibodies were obtained from Professor John Power from the
Alzheimer’s and Parkinson’s laboratory (Flinders University). Phos-
phorylated AMPK rabbit-polyclonal (Thr172, #2531) and AMPKSA0230 (C) M 86 Other Hippocampus 22
PMI = post mortem interval; AD = Alzheimer’s disease; C = Control; M = male;
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52), anti-goat (705-035-003) and goat anti rabbit (111-035-144),
iotinylated donkey anti-rabbit (711-065-152), Alexa Fluor
®
488
onkey anti-rabbit, Alexa Fluor
®
CY3 donkey anti-mouse and
lexa Fluor
®
CY3 donkey anti-sheep were purchased from Jackson
mmunoresearch (West Grove, USA).
.7. Brain homogenate
Frozen tissue from the hippocampus and mid-frontal gyrus
MFG) of six AD and three control cases (human brains) and the
iddle 1/3 (0.3–0.35 g) of the frozen specimens (rat brains) con-
aining parietal cortex and hippocampus were homogenized in
xtraction buffer (50mMTris, 5mMEDTA, 0.1% sodium azide, Pep-
tatinA (Sigma, P5318, 1g/ml), Leupeptin (Sigma, L2884, 1g/ml)
nd phenylmethylsulfonyl ﬂuoride (Sigma, P7626, 100 mM)), cen-
rifuged (1000g/5 min) and the supernatants were analysed.
.8. Protein quantiﬁcation and western blot analysis
The amount of total protein in each samplewas calculated using
n EZQ assay following an approved protocol (Bio-Rad, Hercules,
A). To analyse electrophoretic mobility of p-LKB1, LKB1, p-tau,
au, p-GSK-3, GSK-3, p-PP2A, PP2A, p-CREB, p-AMPK and AMPK,
0 g of each sample was loaded in each well of AnykDTM TGX
tain-free gel (Bio-Rad, CA, USA, 569033), with 1 well containing
L Precision Plus ProteinTM Dual Color Standards (Bio-rad, Her-
ules, CA,USA).Acurrent (300mA)wasapplied to thegel for20min.
amples were blotted using a Bio-Rad Trans-Blot transfer system
it (Bio-Rad, CA, USA). The membranes were blocked for 1 h and
ere incubated overnight (4 ◦C) with primary antibodies of p-tau
Ser262, 1:250), AT8 (Ser202/Thr205, 1:1000), p-GSK-3 (1:500), p-
P2A-C/ (1:500), tau (1:250), GSK-3 (1:500), PP2A-A (1:500),
-LKB1 (1:500), LKB1 (1:500), p-AMPK (1:1000), AMPK (1:1000).
ollowing this the membranes were incubated for 1 h with HRP
econdary antibodies (donkey anti-mouse and anti-rabbit, 1:3000;
onkey anti-goat, 1:10,000). The blotswere developedusing anECL
nd chemiluminescence signal detection was performed using Fuji
AS4000 imager, quantitated by CareStream imaging software, and
ere corrected against actin levels.
.9. Immunohistochemistry (IHC) and immunoﬂuorescent (IF)
(DAB)-metal enhanced IHC and IF staining were undertaken
sing an established process (Power et al., 2015; Majd et al., 2016).
rieﬂy, 5 m brain sections of parietal cortex and hippocam-
us of the rats were deparafﬁnised. After EDTA antigen retrieval,
he sections were incubated with hydrogen peroxidase and horse
erum blocking, followed by incubating with p-tau (Ser296, 1:200),
-AMPK (Thr172, 1:200), p-LKB1 (Ser431, 1:200), p-GSK-3 (Ser9,
:200), tau(1:200), NeuN (1:200) and GFAP (1:200) antibodies
18 h/4 ◦C). The sections were subsequently incubated for 1 h
ith the Biotinylated donkey anti-rabbit, and anti-mouse for IHC
1:1000, Jackson) and Alexa Fluor
®
488 donkey anti-rabbit, CY3
onkey anti-mouse, Alexa Fluor
®
488 donkey anti-mouse and CY3
onkey anti-sheep (1:100, Jackson) for IF. The staining was visu-
lized using a Brightﬁeld Olympus BX50 and Leica SP5 5-channel
aser scanning confocal microscope.
.10. Statistical analysis
All data were analysed using IBM Statistics version of SPSS Soft-
are and the results were expressed as the mean ± SD. One-way
NOVAwasused toassess thedifferencesbetween themeansof the
roups followed by post hoc Tukey’s. Student independent t-tests
ere used to assess the differences between two human groups of
ormal and AD cases. Student Paired t-tests were used to assessorts (2017) 1–13
the difference between NOR and MWM tests before and after CA.
Signiﬁcance was deﬁned as *p < 0.05.
3. Results
3.1. Rat model of reversible global brain ischaemia
A rat model of reversible cardiac arrest (CA) was used to inves-
tigate the effect of ischaemia and recovery from ischaemia, on the
main metabolic axis of LKB1/AMPK. Analysing a series of brain tis-
sue samples, obtained from animals subjected to different periods
of ischaemia/reperfusion showed the following results:
3.1.1. Effect of ischaemia on LKB1/AMPK axis activation
The levels of LKB1 and AMPK phosphorylation were evalu-
ated at different time points to assess the effect of global brain
ischaemia/reperfusion on this main cellular metabolic axis. Fol-
lowing an initial reduction of p-LKB1 (active form) during 2 min
of ischaemia (One Way ANOVA, F3, 20 = 77.16, *p < 0.05), p-LKB1
showed a signiﬁcant increase after 4 weeks of recovery following
CA (OneWayANOVA, F3, 20 = 77.16, P = 0.000538, *p < 0.01) (Fig. 2A).
Thewestern blot resultwas conﬁrmed byDAB staining, showing an
enhanced immunostaining of p-LKB1 in the brains of the rats after
4 weeks recovery (2D. d) compared to the control group (2D. c).
Western blot results showed an enhanced AMPK phosphorylation
level after the same period of 4 weeks recovery following 2 min of
CA (One Way ANOVA, F3, 20 = 224.4, *p < 0.01) (Fig. 2B). These ﬁnd-
ings were supported by the immunoﬂourescent results, showing
higher accumulation of p-AMPK (green) in the long-term recovery
(Fig. 2C d, e, f) compared with the control group (Fig. 2C a, b, c),
with a greater distribution of p-AMPK within the neurons (nuclear
staining with NeuN in red (2D. a)) compared with glial cells (cyto-
plasmic glial ﬁbrillary acidic protein (GFAP) staining in red (2D. b)).
This represents an increase in p-LKB1 and p-AMPK in the 4 weeks
after ischaemia recovery groups as the total amount of AMPK and
the level of -actin remained the same across all lanes (Fig. 2A and
B).
3.1.2. Effect of ischaemia on tau phosphorylation at
AMPK-sensitive epitope (Ser262), and GSK-3ˇ-sensitive epitope
(Ser202/Thr205 (AT8))
Todetermine the involvement of AMPKandGSK-3 in tauphos-
phorylation during ischaemia and reperfusion, the homogenates
containing parietal cortical and hippocampal tissues were used
for Western blot analysis to assess the levels of p-tau (Ser262,
Ser202/Thr205) and total tau in 2min ischaemia and2min ischaemia
followed by 1 h and 4 weeks recovery vs control (anesthesia only).
The actin loading was assessed across the different groups. An
initial reduction in p-tau at Ser262, (AMPK speciﬁc residue) was
followed by a signiﬁcant increase after 4 weeks (One Way ANOVA,
F4, 20 = 96.62, *p < 0.01). AMPK independent but GSK-3 dependent
p-tau (Ser202/Thr205), remained unchanged (Fig. 3A). To examine
the possibility of underlying changes in total tau being responsible
for the observed results the levels of total tau in all groups were
tested. The results showed that 2 min ischaemia did not affect the
total tau while phosphorylation at its AMPK-sensitive residue was
affected (Fig. 3A). The impact of ischaemia on p-tau at Ser262 was
observed in the IF staining after 4 weeks (Fig. 3B), which demon-
strated a signiﬁcant accumulation of p-tau (Ser262) in both soma
and neuronal processes, compared with the control where p-tau
was mostly in the neuronal processes (Fig. 3B).3.1.3. Long-term inﬂuence of 2 min of ischaemia on PKA
To study the possible involvement of PKA in phosphorylating
tau at Ser262 in the 4 weeks recovery after 2 min ischaemia exper-
iment, the level of phosphorylated CREB (p-CREB) was assessed as
S. Majd et al. / IBRO Reports (2017) 1–13 5
Fig. 2. Protein assay of LKB1/AMPK axis: phosphorylated (Active) form of LKB1 (A) and AMPK (B) and the total protein of each (A, B) were analysed via Western blot of the
cortical and hippocampus regions of the control, ischaemic only and ischaemia followed by short-term 60 min and long-term recovery of 4 weeks following 2 min CA (n = 6
each). I-2m: 2 min ischaemia, I-2m/R- 60 m: 2 min ischaemia followed by 60 min reperfusion, I-2m/R- 4w: 2 min ischaemia followed by 4 weeks recovery period (One Way
ANOVA, *p < 0.05 for p-LKB1 in I-2m vs control, *p < 0.01, for p-LKB1 in I-2m/R- 4w vs control; *p < 0.01, for p-AMPK in I-2m, I-2m/R- 60 m and I-2m/R- 4w vs control). Error
bars depict the SD. All values are expressed as percent change relative to control group and were corrected by the Actin level. C) Phosphorylated AMPK (green) presence in
control (Fig. 2C a, b, c) and long-term recovery of 4 weeks (Fig. 2C d, e, f) are visualised by immunoﬂuorescent staining. D) DAPI (blue) shows nuclei staining for all cell types
(both neurons and glial cells). Distribution of p-AMPKwithin the neurons and glial cells are shown by immunoﬂuorescent co-staining with neuronal marker for nuclei (NeuN
(a), red) or cytoplasmic glial ﬁbrillary acidic protein (GFAP (b), red) from the brain samples of long-term recovery group (2min ischaemia followed by 4weeks). Accumulation
of p-LKB1 is shown via DAB staining in long-term recovery group (d) compared with control group (c). (For interpretation of the references to colour in this ﬁgure legend,
the reader is referred to the web version of this article.)
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Fig. 3. A) Western blot tau phosphorylation assay: tau phosphorylation at two epitopes of Ser262 and Ser202/Thr205 (AT8) were analysed following 2 min ischaemia, 2 min
ischaemia followed by 60 min recovery as well as 4 weeks recovery (n = 6 each). Total tau and actin levels are also examined. I-2m: 2 min ischaemia, I-2m/R- 60 m: 2 min
ischaemia followed by 60 min reperfusion, I-2m/R- 4w: 2 min ischaemia followed by 4 weeks recovery period (One Way ANOVA, *p < 0.01, for p-tau (Ser262) in I-2m, I-2m/R-
60 m and I-2m/R- 4w vs control). Error bars depict the SD. All values are expressed as percent change relative to control group and were corrected by the Actin level. B)
The presence of p-tau (Ser262), visualized by immunoﬂuorescent staining which is mainly located in the processes in control group (a, b, c) and in soma and some parts of
processes in the long-term recovery group of 2 min ischaemia followed by 4 weeks (d, e, f). DAPI (blue) shows nuclei staining. (For interpretation of the references to colour
in this ﬁgure legend, the reader is referred to the web version of this article.)
S. Majd et al. / IBRO Rep
Fig. 4. PKA activity assessment: activation of PKA was evaluated by assessing the
level of p-CREB (Ser133) and the total CREB. A) Western blot result from the brain
samples of; control group, 2min ischaemia, and 2min ischaemia followed by 60min
and 4weeks recovery (n = 6 each). B) Analysis of the results of thewestern blot from
the hippocampus and cortex of the same animals were done to test the levels of p-
CREB and CREB. All the groups showed the same level of active CREB, an indicator of
PKA activity. The same level of total CREB was seen across the experimental groups.
All values are expressed as percent change relative to control group and were cor-
rected by the Actin level. I-2m: 2 min ischaemia, I-2m/R- 60 m: 2 min ischaemia
followed by 60 min reperfusion, I-2m/R- 4w: 2 min ischaemia followed by 4 weeks
recovery period. Error bars depict the SD.orts (2017) 1–13 7
an indicator of PKA activity. No signiﬁcant change in the level of
p-CREB was observed between the control, 2 min ischaemia and
2 min ischaemia followed by 4 weeks recovery groups (One Way
ANOVA) (Fig. 4), indicating that a short episode of ischaemia was
not affecting PKA, during 2 min CA and after 4 weeks recovery.
3.1.4. Long-term inﬂuence of 2 min of ischaemia on GSK-3ˇ and
PP2A activities
As GSK-3 activity is controlled by inhibition through its Ser9
phosphorylation, the level of p-GSK-3 (Ser9) and total GSK-3
wereexamined, after long-termrecovery from2minCA.The results
demonstrated the same level of p-GSK-3 (Ser9), indicating unaf-
fected activity of GSK-3 by ischaemia in our model (Fig. 5A). The
same levels of p-PP2A at Tyr307 (inactive form) and PP2A (active
form) were also observed in all groups (OneWay ANOVA) (Fig. 5B).
This data demonstrates that 2 min of ischaemia did not affect
the activity of PP2A during ischaemia, reperfusion or long-term
recovery. IF staining showed the presence of p-GSK-3 (Ser9), with
co-localization with tau in some areas (Fig. 5C), its distribution is
not obviously increased by a short episode of ischaemia in long-
term recovery groups.
3.1.5. Effect of 2 min ischaemia on memory and learning after 4
weeks recovery
To study the effect of a short episode of 2 min brain ischaemia
on learning and spatial memory, these two criteria of cognitive
behaviour were assessed using the NOR and MWM. Object recog-
nition performance was tested 1 h (Fig. 6a, b) and 24 h (Fig. 6c, d)
after training with identical objects. The results showed that the
animals’ learning andmemory (Student paired t-test) had not been
reduced after 2 min CA. The mean latency ﬁnding the platform in
the MWM test, indicating that spatial learning and memory in the
MWMwere not signiﬁcantly different before, and 4weeks after CA
tests (Student paired t-test) (Fig. 6e, f). These results indicate that
the hyperphosphorylation of tau at Ser262 in response to ischaemia
after 4 weeks recovery was not associated with detectable changes
in learning and memory function in this study.
3.2. Human studies in AD and normal brains
To investigate whether the changes seen in response to
ischaemia in animal studies were present in the brains of patients
with AD, control human brains were compared with those from
patients with diagnosed AD on clinical diagnosis and conﬁrmed
histologically and the following results were observed:
3.2.1. Tau phosphorylation at AMPK-sensitive (Ser262) and
GSK-3ˇ-sensitive (AT8) epitopes in hippocampus
To study the possible involvement of AMPK and GSK-3 as a
potential mechanism behind tau phosphorylation in AD, we inves-
tigated the co-elevation of p-tau in two speciﬁc–responsive sites
to two different kinases in the same samples of clinically diag-
nosed AD brains and normal controls. The level of p-tau (Ser262)
and p-tau (Ser202/Thr205 (AT8)) was signiﬁcantly increased in the
hippocampus of AD brains (Student t-test, F1, 7 = Inﬁnity, *p < 0.05),
while the total tau protein decreased (Student t-test, F1, 7 = Inﬁn-
ity, *p < 0.0001). The actin loading was shown across the different
groups (Fig. 7).
3.2.2. AMPK, GSK-3ˇ and PP2A activities in hippocampus of AD
brains
To examine the levels of all three main enzymes in p-tau eleva-
tion inAD, the levels of p-AMPK (Thr172), p-GSK-3 (Ser9) andPP2A
were evaluated, along with the total amount of each enzyme. A
signiﬁcant increase in p-AMPK (Thr172) was seen in AD brains (Stu-
dent t-test, F1, 7 = Inﬁnity, *p < 0.05), while the level of the inactive
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Fig. 5. Evaluating the activities of GSK-3 and PP2A: A) Western blot analyzing of the level of p-GSK-3 at Ser9 and total protein of GSK-3 assessment from control group,
2 min ischaemia, and 2 min ischaemia followed by 60 min and 4 weeks recovery (n = 6 each), where no signiﬁcant changes were observed. B) Western blot analysis of
the hippocampus and cortex of the same animals was performed to examine the levels of PP2A and p-PP2A. All the groups showed the same level of PP2A. All values are
expressed as percent change relative to control group and were corrected by the Actin level. I-2m: 2 min ischaemia, I-2m/R- 60 m: 2 min ischaemia followed by 60 min
reperfusion, I-2m/R- 4w: 2min ischaemia followed by 4 weeks recovery period. (Error bars depict the SD. C) Immunoﬂuorescent results showed the presence of p-GSK-3 at
Ser9 (inactive form; red) with some co-localization with tau protein (green) in the brain sections of the long-term groups of 4 weeks recovery following 2 min cardiac arrest
(CA) contained the hippocampus and parietal cortex. DAPI (blue) shows nuclei staining for all cell types (both neurons and glial cells). (For interpretation of the references
to colour in this ﬁgure legend, the reader is referred to the web version of this article.)
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Fig. 6. Effects of global brain ischaemia on cognitive function after 2 min cardiac arrest (CA) (n = 6). Learning and memory performance were evaluated in novel object







































oc–d) after training with two identical objects. In MWM task, spatial acquisition tri
patial learning and memory ability. Student Paired t-test, Data are expressed as m
orm of GSK-3, p-GSK-3 (Ser9), was decreased (Student t-test,
1, 7 = Inﬁnity, *p < 0.001). The PP2A level also showed a signiﬁcant
ecline (Student t-test, F1, 7 = Inﬁnity, *p < 0.005) in AD brains com-
ared with the normal groups. There were no signiﬁcant observed
hanges in the total proteins levels of AMPK and GSK-3. The actin
oading was shown the across the different groups (Fig. 8).
. Discussion
We investigated site-speciﬁc hyperphosphoryaltion of tau at
er262 and at AT8 (Ser202/Thr205) by AMPK and GSK-3, follow-
ng brain ischaemia and its impact on the learning and memory
f rats. Tau pathology in AD has been documented (Majd et al.,
015;Murray et al., 2015) and the presence of aggregated p-tau fol-
owing brain hypoxia, suggests a link between hypoxia, ischaemia,
D pathological hallmarks and cognitive deﬁcits (Madureira et al.,
001; Chen et al., 2003; Iliff et al., 2014; Zhang et al., 2014). Using a
eversible model of brain ischaemia in adult female rats, Wen et al.
howed an extensive neuronal tauopathy following the ischaemic
nsult, suggesting pathological evidence of developing AD in post-
schaemic brains (Wen et al., 2004, 2007), however it is not
lear how speciﬁc ischaemia induced tau-hyperphosphorylation
ffects cognition. We reported an early pattern of tau dephos-
horylation (Ser262), after 2 min of CA, which was consistent
ith previous reports of tau dephosphorylation in a transient
schaemicmodel of stroke and cardiac arrest (Shackelford and Yeh,
998; Majd et al., 2016). Our data showed no re-phosphorylation
ollowing an hour of reperfusion. Here, we observed signiﬁcant
au hyperphosphorylation at Ser262, a sensitive epitope to AMPK
Thornton et al., 2011; Yoshida and Goedert, 2012) occurring 4
eeks post a 2 min CA. The level of p-tau at AT8 (Ser202/Thr205),
GSK-3 and PKA sensitive but AMPK kinases insensitive residue
Hashiguchi et al., 2002; Liu et al., 2006; Takashima, 2006; Hanger
t al., 2009; Hernandez et al., 2013) did not show any signiﬁcant
hange during ischaemia, or recovery. Tau phosphorylation is a
nown indicator of altered neuronal metabolism (van der Harg
t al., 2014), our results suggested the presence of a metabolic
elated mechanism altering p-tau status in response to alterations
n neuronal oxygen supply.
The LKB1/AMPK axis has a key role as the master controller
f cellular energy balance, in modulating metabolism which isape latency (e) and time in target quadrant (f)) were performed in order to detect
SD.
triggered by hypoxia/anoxia (Hardie, 2011). After being activated
by LKB1, AMPK kinases stimulate catabolic and inhibit anabolic
processes allowing the cells to adapt to hypoxia by adjusting intra-
cellular ATP (Ramamurthy and Ronnett, 2006). It is reported that
blocking the AMPK pathway, reduced tau phosphorylation in a tau
mousemodel of AD, showing a link between activation of themain
cellular responsive kinase to ischaemia and generating p-tau, one
of the main hallmarks of AD (Koppel et al., 2016).
Tau phosphorylation has been suggested as one of the main
functions of the AMPK family of kinases (Thornton et al., 2011; Gu
et al., 2013), which exhibit their main kinase activity on Ser262.
This site is not sensitive to GSK-3 activity, but mainly to AMPK
kinase activation as well as PKA to a lesser extent (Iijima et al.,
2010; Mietelska-Porowska et al., 2014). Hyperphosphorylated tau
at Ser262 has been shown to be neurotoxic due to its reduced abil-
ity to bind to microtubules (Whiteman et al., 2009). We showed
a signiﬁcantly high level of AMPK phosphorylation, along with
tau hyperphosphorylation at Ser262 following 4 weeks recovery
after brain ischaemia. Despite our expectation that this hyper-
phosphorylation might be linked to cognitive deﬁcits, this Ser262
hyperphophorylation did not affect memory function in the ani-
mals as tested in this study. Our ﬁndings from human AD brains
revealed thehyperphosphoryaltionof tauatmultiple sitesof Ser262,
Ser202 and Thr205. We also showed that AD brains contained a
higher level of p-AMPK, an enhanced level of p-GSK-3 at Ser9
and lower levels of PP2A at the same time, while our observations
from animal models of global brain ischaemia, showed no obvi-
ous change in tau phosphorylation at its GSK-3-sensitive epitopes
of Ser202/Thr205, indicating the same total GSK-3 activity during
ischaemia and after long-term recovery. Phosphoryalted GSK-3,
PP2A and PKA along with their total levels also remained almost
constant across all groups. These ﬁndings suggest that tau phos-
phorylation in response to a short term ischaemia is linked toAMPK
kinases rather than GSK-3, PP2A or PKA, and raised the possibility
of requirement of a combination of tau kinase/phosphatase activity
involvingmultiple phosphorylation sites in order to affectmemory
function.Our ischaemic model provided the opportunity to separate the
effects of tau phosphorylation (Ser262) from phosphorylation at
Ser202/Thr205. An in vitro study showed that tau phosphorylated
at Ser262 decreased the tau assembly into paired helical ﬁlaments
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Fig. 7. Tau phosphorylation assessment in two speciﬁc residues of Ser262 and Ser202/Thr205 (AT8) from the human brains of Alzheimer’s disease (AD) (n = 6) and normal
groups (n = 3) (N): western blot analysis p-tau (Ser262 and Ser202/Thr205 (AT8)) showed the elevation of both forms of p-tau in the AD brains compared with normal groups

















prains (Student t-test, *p < 0.05). Total tau protein was also tested via western blo
ame patients, showing a decrease in the total tau expression (Student t-test, *p < 0
he SD. All values are expressed as percent change relative to control group and we
Schneider et al., 1999). Our data revealed that hyperphospho-
ylation of Ser262 alone after ischaemia was not associated with
emory and learning impairement in this study. Previous studies
ave reported that hyperphosphorylated tau is involved in dys-
unctional axonal transport with evidence of a toxic effect of tau
hosphorylated at (Ser262), especially in the presence of beta amy-
oid (Chatterjee et al., 2009; Iijima et al., 2010). In our study, we
ound extensive phosphorylation of tau at both Ser262 and AT8
esidues in human AD brains, associated with elevation of AMPK
nd GSK-3, however our animal model, exposed to ischaemia
nly showed Ser262 hyperphosphorylation, unchanged AT8, and
nchangedGSK3B, PP2A, PKAphosphorylatedand total levels along
ith unaffected memory function in rats. We propose that tau
yperphosphorylation at Ser262 occurred mainly due to AMPK
athway activation, as we showed that PKA levels, the other kinasee same brain samples from the hippocampus and mid-frontal gyrus (MFG) of the
). The actin loading has been showed across the different groups. Error bars depict
rected by the Actin level.
with potential tau kinase activity at Ser262 (Mietelska-Porowska
et al., 2014), remained unchanged. AMPK has been suggested to
be a protective metabolic mechanism allowing neurons to com-
pensate for prior ischaemic damage (Russell et al., 2004), and
some reports have shown that its activation inactivates GSK-3
through phosphorylation of Ser9 (Horike et al., 2008). Some stud-
ies, howeverhave suggested that hypoxiadirectly activatesGSK-3
(Roh et al., 2005). Observing no adverse impact following a short
episode of ischaemia on memory and learning in our study, we
hypothesize that ischaemic-derived activation of AMPK protects
the cell by returning the ischaemic-derived GSK-3 hyperactiv-
ity to a normal level, with a possible protective effect against tau
aggregation through the modulating effect of p-AMPK on GSK-3.
It is alsohypothesized that Ser262 phosphorylationunder ischaemic
situations acts as an initial trigger, enhancing the phosphoryla-
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Fig. 8. AMPK, GSK-3 and PP2A assessment: phosphorylated forms of AMPK, GSK-3 (Ser9) and PP2A (Tyr307) along with the un-phosphorylated forms were examined via
western blot analysing in the human brain samples (hippocampus and mid-frontal gurus) of Alzheimer’s disease (AD) (n = 6) and normal groups (N) (n = 3). Phosphorylated
AMPK (Thr172) was increased in AD brains compared with the normal groups (Student t-test, *p < 0.05). The levels of p-GSK-3 at Ser9 (inactive form) and PP2A (active
form) were decreased (*p < 0.001 and *p < 0.005, respectively) in AD cases where the total level of AMPK, GSK-3 and p-PP2A (inactive form) did not show any signiﬁcant
changes. The actin loading has been showed across the different groups. Error bars depict the SD. All values are expressed as percent change relative to control group and
























































f2 S. Majd et al. / IBR
ion of tau over longer periods of time (up to 20 years) (Amieva
t al., 2014) taken for a patient to develop the symptoms of AD.
ecent researchusing tau toxicitymodels, demonstrated that phos-
horylation at Ser262 promoted further phosphorylation at the
ossible GSK3-phosphorylated epitopes of AT8 (Bertrand et al.,
010). The signiﬁcantly higher level of p-AMPK in the hippocam-
us and MFG of AD patients in our study was consistent with
ormer reports (Thornton et al., 2011; Vingtdeux et al., 2011), pro-
iding more evidence for multifactorial-based mechanism for AD
athogenesis, however if the progressive neurodegenerative fea-
ures of the disease could be a direct involvement of an individual
inase/phosphatase or the combination of them, is a question that
equires further investigations. Our ﬁndings demonstrated a sub-
tantial decrease in p-GSK-3 at Ser9 (inactive form), along with
educed activity of PP2A in the AD affected brains. Considering our
esults from animal and human studies and the results of previ-
us studies (Lovell et al., 2004; Liu et al., 2005; Vingtdeux et al.,
011), we suggest that AMPK triggers a change in tau phosphor-
lation status following an alteration in cellular energy, initially
odulating the GSK-3 activity, then triggering further tau phos-
horylation over a longer period of time. Although the hypothesis
hat changes in AMPK activity and tau phosphorylation at Ser262
s placed upstream of further tau phosphorylation by the other
inases (including GSK-3) still remains to be substantiated, we
uggest that memory impairment is not a consequence of Ser262
au hyperphosphorylation alone and the involvement of GSK-3,
ometimes associated with PP2A remains a requirement for the
reation of cognitive deﬁcits, as seen in AD patients.
. Conclusions
This study demonstrated the activation of the LKB1/AMPK axis
econdary to ischaemia leading to hyperphosphorylation of tau at
he AMPK-sensitive epitope (Ser262) after 4weekswith no involve-
ent of GSK-3 or PP2A and no cognition/memory deﬁcits, while
ur AD brain study showed elevated p-AMPK (Thr172) and p-GSK-
 (Ser9) and reduced PP2A levels. We propose that AMPK begins
he process of tau phosphorylation in response to ischaemia with a
ossible modulating inﬂuence on GSK-3 initially however phos-
horylation at Ser262 may facilitate tau phosphorylation in other
esidues, in situations of prolonged hypoxia. We suggest that a
SK-3 and/or PP2A presence is required to produce memory
mpairment associated with metabolic disturbances in the brain
nvironment. The speciﬁc impact of the early activatedAMPKpath-
ay on the other tau kinases and the level of involvement of
ifferent AMPK kinases in generating the observed phenomenon
esponsible for tau hyperphosphorylation in response to hypoxia
emained to be evaluated in our future studies, particularly if the
ypoxic insult persists or is repeated.
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